Abbott Laboratories Stock Buy Recommendation Reiterated (ABT)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK (TheStreet) -- Abbott Laboratories (NYSE:ABT) has been reiterated by TheStreet Ratings as a buy with a ratings score of A+ . The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

• ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Highlights from the ratings report include:

• ABT's revenue growth has slightly outpaced the industry average of 5.9%. Since the same quarter one year prior, revenues slightly increased by 2.0%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
• The debt-to-equity ratio is somewhat low, currently at 0.74, and is less than that of the industry average, implying that there has been a relatively successful effort in the management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.04, which illustrates the ability to avoid short-term cash problems.
• Compared to its closing price of one year ago, ABT's share price has jumped by 30.47%, exceeding the performance of the broader market during that same time frame. Regarding the stock's future course, although almost any stock can fall in a broad market decline, ABT should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
• The gross profit margin for ABBOTT LABORATORIES is currently very high, coming in at 70.40%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 17.60% is above that of the industry average.
• ABBOTT LABORATORIES's earnings per share declined by 12.2% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, ABBOTT LABORATORIES increased its bottom line by earning $2.99 versus $2.96 in the prior year. This year, the market expects an improvement in earnings ($5.05 versus $2.99).

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. The company has a P/E ratio of 21.4, above the average drugs industry P/E ratio of 21.3 and above the S&P 500 P/E ratio of 17.7. Abbott has a market cap of $103.18 billion and is part of the health care sector and drugs industry. Shares are up 16.9% year to date as of the close of trading on Thursday.

You can view the full Abbott Ratings Report or get investment ideas from our investment research center.

--Written by a member of TheStreet Ratings Staff.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free Download Now

For more information on Abbott Laboratories click any of the following:

• Abbott Laboratories Stock Price

• Abbott Laboratories Analyst Ratings

• Abbott Laboratories Key Stats & Profile

• Abbott Laboratories Earnings

• Abbott Laboratories Ratio Comparison

• Abbott Laboratories Growth Rates

• Abbott Laboratories Balance Sheet

• Abbott Laboratories Cash Flow

• Abbott Laboratories Income Statement